Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and markets pain management medications. The company is headquartered in Stoughton, Massachusetts.
| Revenue (TTM) | $808.21M |
| Gross Profit (TTM) | $722.93M |
| EBITDA | $405.25M |
| Operating Margin | 5.65% |
| Return on Equity | 17.60% |
| Return on Assets | 5.76% |
| Revenue/Share (TTM) | $25.30 |
| Book Value | $9.51 |
| Price-to-Book | 4.65 |
| Price-to-Sales (TTM) | 1.01 |
| EV/Revenue | 2.161 |
| EV/EBITDA | 5.01 |
| Quarterly Earnings Growth (YoY) | -46.60% |
| Quarterly Revenue Growth (YoY) | 6.30% |
| Shares Outstanding | $32.56M |
| Float | $29.77M |
| % Insiders | 1.15% |
| % Institutions | 128.49% |
Volatility is currently expanding
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.96 per share, beating the Zacks Consensus Estimate of $1.77 per share. This compares to earnings of $2.25 per share a year ago.
The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Collegium Pharmaceutical NASDAQ: COLL reported record third-quarter 2026 revenue as growth in its attention-deficit/hyperactivity disorder portfolio helped offset declining sales of pain medicines. The company reaffirmed its full-year outlook, though quarterly earnings fell from a year earlier.
– Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year – – Generated Record JORNAY PM ® Quarterly Net Revenue of $51.9 Million, Up 24% Year-over-Year – – Generated AZSTARYS ® Quarterly Net Revenue of $26.5 Million in First Full Quarter of Sales Under Collegium Ownership – – Generated Quarterly Pain Portfolio Net Revenues of $138.0 Million – – Announced $50 Million Accelerated Share Repurchase in Q3'26 – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass.
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Collegium Pharmaceutical (COLL) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two stocks offers value investors a better bang for their buck right now?
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New multi-year partnership combines youth coach training, an annual Sports for All Summit, and sensory inclusion programs to support neurodivergent children and families New multi-year partnership combines youth coach training, an annual Sports for All Summit, and sensory inclusion programs to support neurodivergent children and families
STOUGHTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it will report third quarter 2026 financial results before the market opens on Thursday November 5, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET.
Seven presentations include pediatric Phase 4 studies of AZSTARYS® (Serdexmethylphenidate/dexmethylphenidate) CII and real-world research of JORNAY PM® (Delayed-Release/Extended-Release Methylphenidate) CII in adults and impact on caregivers Seven presentations include pediatric Phase 4 studies of AZSTARYS® (Serdexmethylphenidate/dexmethylphenidate) CII and real-world research of JORNAY PM® (Delayed-Release/Extended-Release Methylphenidate) CII in adults and impact on caregivers
Investors interested in Medical - Drugs stocks are likely familiar with Collegium Pharmaceutical (COLL) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on COLL and any ticker you trade — then tracks every position and per-strategy win rate.
